Impel NeuroPharma Revenue and Competitors

Seattle, WA USA

Location

$211.3M

Total Funding

Estimated Revenue & Valuation

  • Impel NeuroPharma's estimated annual revenue is currently $44.9M per year.(i)
  • Impel NeuroPharma received $67.5M in venture funding in December 2018.
  • Impel NeuroPharma's estimated revenue per employee is $313,750
  • Impel NeuroPharma's total funding is $211.3M.

Employee Data

  • Impel NeuroPharma has 143 Employees.(i)
  • Impel NeuroPharma grew their employee count by -30% last year.

Impel NeuroPharma's People

NameTitleEmail/Phone
1
VP Commercial Operations & AnalyticsReveal Email/Phone
2
VP Clinical Development & OperationReveal Email/Phone
3
VP SalesReveal Email/Phone
4
Chief Technology & Development OfficerReveal Email/Phone
5
Director, Life SciencesReveal Email/Phone
6
Chief Commercial OfficerReveal Email/Phone
7
Senior Director, Market AccessReveal Email/Phone
8
Senior Clinical Data ManagerReveal Email/Phone
9
Sr. Clinical Trial LeadReveal Email/Phone
10
Neurology Sales SpecialistReveal Email/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$4.9M39117%$14.9MN/A
#2
$44.9M143-30%$211.3MN/A
#3
$54M17211%$35.5MN/A
#4
$4.3M17-19%N/AN/A
#5
$18.3M73N/AN/AN/A
#6
$8.3M336%N/AN/A
#7
$81.1M32317%N/AN/A
#8
$7M28-12%N/AN/A
#9
$204.8M8163%N/AN/A
#10
$6.3M5025%$27.5MN/A
Add Company

What Is Impel NeuroPharma?

Impel NeuroPharma, Inc., is a privately-held, Seattle-based company devoted to creating life-changing, innovative therapies for central nervous system (CNS) diseases. Impel's products are based on a novel nasal drug delivery platform, the POD device, that administers drug to the upper nasal cavity in a consistent and predictable manner. Impel NeuroPharma is currently investigating INP104 (POD DHE) for acute migraine headache, INP103 (POD levodopa) for Parkinson's Disease, INP105 (POD olanzapine) for agitation in schizophrenia and bipolar disorders as well as INP102 (POD insulin) for Alzheimer's disease in an NIH funded trial. Impel NeuroPharma's proprietary POD device enables small and large molecule drugs to be administered using a cost-effective, disposable, non-invasive intranasal drug delivery device. To learn more about Impel NeuroPharma, please visit our website at http://impelnp.com.

keywords:Biotechnology,Cleantech,Healthcare,Medical Devices,Pharmaceuticals,Wind Power

$211.3M

Total Funding

143

Number of Employees

$44.9M

Revenue (est)

-30%

Employee Growth %

N/A

Valuation

N/A

Accelerator

Impel NeuroPharma News

2022-04-17 - Impel Neuropharma Announces Company Will Now Be ...

SEATTLE, April 25, 2022 (GLOBE NEWSWIRE) -- Impel NeuroPharma (NASDAQ: IMPL), a commercial-stage pharmaceutical company developing...

2022-04-17 - Impel NeuroPharma rebrands to Impel Pharmaceuticals as ...

Impel NeuroPharma (Nasdaq:IMPL) announced today that it changed its name to Impel Pharmaceuticals as part of a corporate rebrand.

2022-04-13 - Impel NeuroPharma to Ring Nasdaq Closing Bell on Monday ...

SEATTLE, April 21, 2022 (GLOBE NEWSWIRE) -- Impel NeuroPharma (NASDAQ: IMPL), a commercial-stage pharmaceutical company developing...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$22M143-3%N/A
#2
$38.9M1447%$17.2M
#3
N/A1447%N/A
#4
$52M1447%N/A
#5
$35.1M1458%$3M

Impel NeuroPharma Funding

DateAmountRoundLead InvestorsReference
2013-11-29$2.6MUndisclosedArticle
2015-10-15$12.0MB3M New VenturesArticle
2016-09-01$1.1MUndisclosedArticle
2016-12-05$36.0MCvenBIOArticle
2018-12-07$67.5MDKKRArticle